EMA News
EMA PRAC Warns of Aseptic Meningitis Risk with Ixchiq Vaccine
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended updating the product information for the chikungunya vaccine Ixchiq to reflect recent evidence of aseptic meningitis risk, particularly in healthy young adults. This follows a safety signal investigation and is part of a regular safety assessment.
Priority review
Guidance
Pharmaceuticals
Source details
Activity
Browse Categories
Get Drug Approvals alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get EMA News alerts
We'll email you when EMA News publishes new changes.